Valuation: CEL-SCI Corporation

Market Cap 24.98M 21.39M 20.02M 18.32M 34.39M 2.39B 34.84M 237M 92.23M 1.2B 93.78M 91.74M 3.97B P/E 2026 *
-0.46x
P/E 2027 * -0.22x
Enterprise Value 19.42M 16.64M 15.57M 14.25M 26.74M 1.86B 27.1M 184M 71.72M 934M 72.93M 71.34M 3.09B EV / Sales 2026 *
-
EV / Sales 2027 * 3.29x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day-2.74%
1 week-7.79%
Current month+22.41%
1 month+15.45%
6 months-70.42%
Current year-73.00%
1 week 1.42
Extreme 1.42
1.69
1 month 1.14
Extreme 1.14
1.75
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
13.48
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
387.04
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Date Insider Type Main position Quantity % Market Cap.
14/08/26 Free

Chief Financial Officer

225,000 1.2874%
14/08/26 Free

Director

110,000 0.6294%
14/08/26 Free

General Counsel

80,000 0.4577%
Change 5-day change 1-year change 3-year change Capi.($)
-2.74%-7.79%-85.08%-96.60% 24.82M
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +0.85%+6.75%+44.67%+168.25% 28.95B
Weighted average by Cap. +0.74%+9.48%+58.01%+157.84%

Financials

2026 *2027 *
Net sales - 5.97M 5.12M 4.79M 4.38M 8.22M 571M 8.33M 56.55M 22.05M 287M 22.42M 21.94M 949M
Net income -25.08M -21.49M -20.1M -18.4M -34.54M -2.4B -34.99M -238M -92.63M -1.21B -94.19M -92.14M -3.99B -29.51M -25.28M -23.66M -21.65M -40.64M -2.82B -41.17M -279M -109M -1.42B -111M -108M -4.69B
Net Debt -5.55M -4.76M -4.45M -4.07M -7.65M -531M -7.75M -52.59M -20.51M -267M -20.85M -20.4M -883M -5.34M -4.57M -4.28M -3.92M -7.35M -511M -7.45M -50.56M -19.72M -257M -20.05M -19.61M -849M
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
21/08/26 $1.420 -2.74% 66,143
20/08/26 $1.460 -10.98% 183,495
19/08/26 $1.640 +3.14% 184,790
18/08/26 $1.590 +2.58% 228,788
17/08/26 $1.550 +0.65% 129,424
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.420USD
Average target price
12.50USD
Spread / Average Target
+780.28%

Annual profits - Rate of surprise